

Rabbit Anti-phospho-Tau (Thr498)antibody

SL0885R

Product Name phospho-Tau (Thr498)

Chinese Name 磷酸化微管相关蛋白抗体

Alias Tau(Phospho-Thr498); MAPT(phospho T498);Tau(Phospho-Thr498); MAPT; Microtubule-associated protein Tau; AI413597; AW045860; DDPAC; Disinhibition dementia parkinsonism amyotrophy FLJ31424; FTDP 17; FTDP17; G Protein beta 1 gamma 2 subunit interacting factor 1; G protein beta1/gamma2 subunit interacting factor 1; MAPTL; MGC134287; MGC138549; MGC156663; Microtubule associated protein tau isoform 4; MSTD; Mtapt; MTBT1; MTBT2; Neurofibrillary protein; Paired helical filament tau; PHF tau; PHF-tau; PPND; pTau; RNPTAU; Tauopathy and tauopathy failure, included; TAU_HUMAN.

Product Type Phosphorylated anti

Research Area Cell biology immunology Neurobiology Signal transduction transcriptional regulatory factor

Immunogen Species Rabbit

Clonality Polyclonal

React Species Human, Mouse, Rat, (predicted: Dog, Pig, Cow, Rabbit,)
WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:50-200,Flow-Cytometry
(Paraffin sections need antigen repair)

Applications not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.

Theoretical molecular weight 52/79kDa

Cellular localization cytoplasmic The cell membrane

Form Liquid

Concentration 1mg/ml

immunogen KLH conjugated Synthesised phosphopeptide derived from human Tau around the phosphorylated Thr498: PK(p-T)PP

Lsotype IgG

Purification affinity purified by Protein A

Buffer 1M TBS(pH7.4) with 1% BSA, 3% Proclin300 and 50% Glycerol.

**Solution****Storage**

Shipped at 4°C. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.

Attention

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

PubMed

[PubMed](#)

Tau proteins are important Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. Tau proteins subcellular localization: axons of neurons, in the cytosol and in association with plasma membrane components. It expressed in neurons. PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.

Function:

Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.

Product Detail**Subunit:**

Interacts with PSMC2 through SQSTM1. Interacts with SQSTM1 when polyubiquitinated. Interacts with FKBP4. Binds to CSNK1D. Interacts with SGK1.

Subcellular Location:

Cytoplasm, cytosol. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasmic microtubule cytoskeleton. Cell projection, axon. Note=Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.

Tissue Specificity:

Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.

Post-translational modifications:

Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinase (PDPK1: CDK1, CDK5, GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in the form associated with paired helical filaments (PHF-tau)), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK1 or MARK2), causing detachment from microtubules, and their disassembly. Phosphorylation decreases with age.

Phosphorylation within tau/MAP's repeat domain or in flanking regions seems to reduce tAU/MAP's

interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis. Phosphorylation at Ser-548 by PLK1 reduces ability to bind and stabilize microtubules. Phosphorylation at Ser-579 by BRSK1 and BLNK in neurons affects ability to bind microtubules and plays a role in neuron polarization. Phosphorylation on Ser-554, Ser-579, Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 by SGK1 inhibits microtubule depolymerization and neurite formation in hippocampal neurons. There is a reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes the O-GlcNAcylation on this site, while phosphorylation on Ser-713 and Ser-721 reduces glycosylation by a factor of 2 and 4 respectively. Phosphorylation on Ser-721 is reduced by about 41.5% when O-GlcNAcylation on Ser-717.

Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by proteasome. PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.

O-glycosylated. O-GlcNAcylation content is around 8.2%. There is reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes the O-GlcNAcylation on this site, while phosphorylation on Ser-713 and Ser-721 reduces O-GlcNAcylation by a factor of 2 and 4 respectively. O-GlcNAcylation on Ser-717 decreases the phosphorylation on Ser-713 by about 41.5%.

Glycation of PHF-tau, but not normal brain TAU/MAPT. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine lead to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing microtubules and aggregation leading to tangle formation in AD.

DISEASE:

Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). O-GlcNAcylation is greatly reduced in Alzheimer disease brain cerebral cortex leading to an increase in TAU/MAPT phosphorylations.

Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. The form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and neurons.

Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions.

known as Pick bodies that disproportionately affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.

Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap with Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.

Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104]; abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by a parkinsonian-akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs, and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are seen in diseased brains. Most cases appear to be sporadic, with a significant association with a common mutation including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant mode of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of various mutations, including a deletion of Asn-613.

Defects in MAPT are a cause of Parkinson-dementia syndrome (PARDE) [MIM:260540]. A syndrome characterized by parkinsonism tremor, rigidity, dementia, ophthalmoparesis and pyramidal signs. Neurofibrillary degeneration occurs in the hippocampus, basal ganglia and brainstem nuclei.

Similarity:

Contains 4 Tau/MAP repeats.

SWISS:

P10636

Gene ID:

4137

Database links:

[Entrez Gene: 281296](#) Cow

[Entrez Gene: 4137](#) Human

[Entrez Gene: 17762](#) Mouse

[Entrez Gene: 29477](#) Rat

[Omim: 157140](#) Human

[SwissProt: P29172](#) Cow

[SwissProt: P10636](#) Human

[SwissProt: P10637](#) Mouse

[SwissProt: P19332](#) Rat


[Unigene: 101174](#) Human

[Unigene: 1287](#) Mouse

[Unigene: 2455](#) Rat


P-tau 蛋白是脑内神经元细胞支架蛋白之一。其正常功能是促进微管蛋白组成微管，并维持微管的稳定性。参与维持细胞形态、信息传递、细胞分裂等重要生物学过程，是轴突生长神经元极性形成的不可缺少因素。近年来发现 tau 蛋白与一些中枢神经系统变性疾病密切相关。神经 Tau 具有启动微管系统的装配以及稳定微管系统的作用，该蛋白的错误折叠与老年性神经退行性疾病密切相关。

**Product
Picture**




Paraformaldehyde-fixed, paraffin embedded (Mouse cerebellum); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 15 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with

(phospho-Tau (Thr498)) Polyclonal Antibody, Unconjugated (SL0885R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.



Paraformaldehyde-fixed, paraffin embedded (Rat brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 min; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (phospho-Tau (Thr498)) Polyclonal Antibody, Unconjugated (SL0885R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.



Tissue/cell:SH-SY5Y cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 30 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (phospho-Tau (Thr498)) polyclonal Antibody, Unconjugated (SL0885R) 1:100, 90 minutes at 37°C followed by a FITC conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (C02-04002) was used to stain the cell nuclei.